GlobeNewswire: Vyant Bio, Inc. Contains the last 10 of 83 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T18:54:02ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/12/26/2801092/0/en/Vyant-Bio-Provides-Update-on-Winddown-Activities.html?f=22&fvtc=4&fvtv=57241Vyant Bio Provides Update on Winddown Activities2023-12-26T14:15:00Z<![CDATA[CHERRY HILL, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is providing an update to shareholders regarding its winddown activities pursuant to its Plan of Liquidation and Dissolution following the sale of substantially all of its assets. Vyant Bio’s Board of Directors has filed its Certificate of Dissolution with the State of Delaware with an effective time of 5:00 p.m. on December 29, 2023, after which the Company’s stock will cease trading on the OTC, and the holders of shares of the Company’s common stock will cease to have any rights in respect of that stock, except the right of holders at such time to receive distributions, if any, pursuant to and in accordance with the Plan of Dissolution.]]>https://www.globenewswire.com/news-release/2023/11/10/2778509/0/en/Vyant-Bio-Provides-Update-on-Winddown-Activities.html?f=22&fvtc=4&fvtv=57241Vyant Bio Provides Update on Winddown Activities2023-11-10T21:05:00Z<![CDATA[CHERRY HILL, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is providing an update to shareholders regarding its winddown activities pursuant to its Plan of Liquidation and Dissolution following the sale of substantially all of its assets. Vyant Bio’s Board of Directors currently anticipates that it will file a Certificate of Dissolution with the State of Delaware in late December 2023, after which the Company’s common stock will cease to trade and holders of shares of the Company’s common stock will cease to have any rights in respect of that stock, except the right of holders at the date we file the Certificate of Dissolution to receive distributions, if any, pursuant to and in accordance with the Plan of Dissolution.]]>https://www.globenewswire.com/news-release/2023/11/01/2771502/0/en/Vyant-Bio-Announces-Stockholder-Approval-of-Plan-of-Dissolution.html?f=22&fvtc=4&fvtv=57241Vyant Bio Announces Stockholder Approval of Plan of Dissolution2023-11-01T15:45:00Z<![CDATA[CHERRY HILL, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is announcing the results of its special meeting of stockholders on November 1, 2023 (the “Special Meeting”).]]>https://www.globenewswire.com/news-release/2023/10/24/2765997/0/en/Vyant-Bio-Announces-Completion-of-StemoniX-Asset-Sale.html?f=22&fvtc=4&fvtv=57241Vyant Bio Announces Completion of StemoniX Asset Sale2023-10-24T20:00:00Z<![CDATA[CHERRY HILL, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) announced that it has completed the sale of all or substantially all of the assets of the Company (the “Sale”) pursuant to an Asset Purchase Agreement dated July 13, 2023.]]>https://www.globenewswire.com/news-release/2023/10/19/2763463/0/en/Vyant-Bio-Announces-Stockholder-Approval-of-Proposed-Asset-Sale-64-110-Votes-Needed-to-Approve-Plan-of-Dissolution-and-Adjournment-of-Special-Meeting-of-Stockholders.html?f=22&fvtc=4&fvtv=57241Vyant Bio Announces Stockholder Approval of Proposed Asset Sale; 64,110 Votes Needed to Approve Plan of Dissolution; and Adjournment of Special Meeting of Stockholders2023-10-19T15:45:00Z<![CDATA[CHERRY HILL, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) announced that its special meeting of stockholders on October 19, 2023 (the “Special Meeting”) was reconvened resulting in the approval of the sale of all or substantially all of the assets of the Company.]]>https://www.globenewswire.com/news-release/2023/10/11/2758627/0/en/Vyant-Bio-Announces-77-522-Votes-Needed-to-Approve-Sale-of-Assets-175-721-Votes-Needed-to-Approve-Winddown-of-Business-Adjournment-of-Special-Meeting-of-Stockholders.html?f=22&fvtc=4&fvtv=57241Vyant Bio Announces 77,522 Votes Needed to Approve Sale of Assets 175,721 Votes Needed to Approve Winddown of Business Adjournment of Special Meeting of Stockholders2023-10-11T15:45:00Z<![CDATA[CHERRY HILL, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 28, 2023 (the “Special Meeting”) was reconvened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposals as described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on August 16, 2023 (the “Proxy Statement”).]]>https://www.globenewswire.com/news-release/2023/09/28/2751460/0/en/Vyant-Bio-Announces-Adjournment-of-Special-Meeting-of-Stockholders.html?f=22&fvtc=4&fvtv=57241Vyant Bio Announces Adjournment of Special Meeting of Stockholders2023-09-28T15:45:00Z<![CDATA[CHERRY HILL, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 28, 2023 (the “Special Meeting”) was reconvened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposals as described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on August 16, 2023 (the “Proxy Statement”).]]>https://www.globenewswire.com/news-release/2023/09/20/2746767/0/en/Vyant-Bio-Announces-Adjournment-of-Special-Meeting-of-Stockholders.html?f=22&fvtc=4&fvtv=57241Vyant Bio Announces Adjournment of Special Meeting of Stockholders2023-09-20T17:00:00Z<![CDATA[CHERRY HILL, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT), today announced that its special meeting of stockholders on September 20, 2023 (the “Special Meeting”) was convened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposals as described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on August 16, 2023 (the “Proxy Statement”).]]>https://www.globenewswire.com/news-release/2023/05/12/2667756/0/en/Vyant-Bio-Announces-Last-Day-of-Trading-on-Nasdaq-and-Filing-of-Form-15-for-Voluntary-Nasdaq-Delisting-and-SEC-Deregistration.html?f=22&fvtc=4&fvtv=57241Vyant Bio Announces Last Day of Trading on Nasdaq and Filing of Form 15 for Voluntary Nasdaq Delisting and SEC Deregistration2023-05-12T12:00:00Z<![CDATA[CHERRY HILL, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is a biotechnology company that incorporates innovative biology and data science to improve drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. As previously announced, Vyant Bio filed a Form 25 with the Securities and Exchange Commission (the “SEC”) on May 4, 2023 to voluntary delist its securities from The Nasdaq Capital Market (“Nasdaq”).]]>https://www.globenewswire.com/news-release/2023/05/04/2662120/0/en/Vyant-Bio-Announces-Filing-of-Form-25-for-Voluntary-Nasdaq-Delisting-and-SEC-Deregistration.html?f=22&fvtc=4&fvtv=57241Vyant Bio Announces Filing of Form 25 for Voluntary Nasdaq Delisting and SEC Deregistration2023-05-04T20:30:00Z<![CDATA[CHERRY HILL, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is a biotechnology company that incorporates innovative biology and data science to improve drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s proprietary central nervous system (“CNS”) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. As previously announced on April 24, 2023, Vyant Bio notified The Nasdaq Stock Market LLC of its intention to voluntarily delist its shares of common stock, par value $0.0001 per share (the “Common Stock”) from the Nasdaq Capital Market (“Nasdaq”) and deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).]]>